Invests in
Stages:
Locations:
Min Investment:
$500,000.00Max Investment:
$15,000,000.00Target Investment:
$7,000,000.00
Skills
Education
Lists including Geoffrey von
Investments
Work Experience
2009
General Partner
2009
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $100 billion in aggregate value. www.FlagshipPioneering.com.
2022
Founding CEO, Exec Chair
2022
Quotient Therapeutics is the first company to systematically study the genetic variation and evolution of the trillions of cells inside the human body. The company's Somatic Genomics platform reveals novel links between genes and disease across a broad range of therapeutic areas, enabling the discovery of transformative medicines intended to cure, prevent, or reverse disease. Founded by Flagship Pioneering in 2022, Quotient is backed by experts in the field of somatic genetics.
2018
Founding CEO, Chairman of Board
2018
Tessera Therapeutics is a life sciences company pioneering Gene Writing™, a new biotechnology designed to offer scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome of any cell, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing, while eliminating important limitations in their reach, utilization and efficacy.
Founding CEO, Board member
2017
Generate Biomedicines is an early-stage life sciences company pioneering a machine learning– powered biomedicines platform with the potential to generate new drugs on demand across a wide range of biologic modalities—from short peptides to complex antibodies, enzymes, cytokines, and yet to be described protein compositions. Generate Biomedicine’s multimodality generation platform represents a potentially fundamental shift in what’s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering.
2013
Founding CEO, Chief Innovation Officer, and Board Member
2013
Indigo improves grower profitability, environmental sustainability, and consumer health through the use of natural microbiology and digital technologies. Utilizing beneficial plant microbes and agronomic insights, Indigo works with growers to sustainably produce high quality harvests. The company then connects growers and buyers directly to bring these harvests to market. Working across the supply chain, Indigo is furthering its mission of harnessing nature to help farmers sustainably feed the planet. In 2019, Indigo was ranked #1 on CNBC’s Disruptor 50 list and #35 on Fast Company’s Most Innovative Companies list. The company is headquartered in Boston, MA, with additional offices in Memphis, TN; Research Triangle Park, NC; Sydney, Australia; Buenos Aires, Argentina; and São Paulo, Brazil.
2018
Co-Founder and Board Member
2018
Sana Biotechnology, Inc. is a new company focused on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. We are a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change how we approach treating disease. www.Sana.com
2016
Founding CEO and Board Member
2016
Cobalt Biomedicine was founded to develop a new class of therapeutics with ability to deliver essentially any biological payload, ranging from specific biomolecules (genes, RNA, proteins) to cellular organelles with unprecedented cell specificity. Cobalt's approach involved systematically discovering and engineering fusogens-- the proteins that allow cells, vesicles, and viruses to fuse with cell membranes-- across every branch on the tree of life to enable direct and highly targeted therapeutic intervention inside of any or every cell type in the human body. Cobalt Biomedicine was merged with Sana Biotechnology in early 2019.
2015
Founding CEO and Board Member
2015
Kaleido Biosciences is a healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company’s Microbiome Metabolic Therapies (MMT™) are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates to address a variety of diseases and conditions with significant unmet patient needs. The Company’s human-centric discovery and development offers the potential to be faster and more cost-efficient than traditional drug development. https://kaleido.com.
2010
Co-Founder, CTO (2010-2012)
2010
Seres Therapeutics, Inc. (Nasdaq:MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. SER-287 is currently being evaluated in a Phase 2B study in patients with active mild-to-moderate ulcerative colitis. Seres is advancing SER-401 to augment the efficacy of immuno-oncology treatment. In addition, the Company has several other microbiome therapeutic candidates in preclinical development for various serious diseases. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.
2009
Co-Founder, VP Discovery (2009-2013)
2009
Axcella is designing and developing novel endogenous metabolic modulator compositions to safely reprogram metabolic dysregulation. We are transforming the discovery and development of traditional drug and consumer health candidates from concept to clinical stages, by leveraging our deep understanding of human biology. Our novel approach rapidly gains unprecedented information in a capital efficient manner. Our platform has already produced a rich pipeline of product candidates in programs targeting liver, muscle, and CNS. Axcella Health was founded by Flagship Pioneering. www.axcellahealth.com